Abstract
Dying patients experience a heavy symptom burden. Cancer patients,
especially those with advanced disease, may be more likely to face
extremely frightening and less manageable circumstances than
patients with other chronic or life-limiting diseases. In cancer
patients, pain is one of the most feared and burdensome symptoms.
Not only do patients with cancer commonly report fears of a
prolonged death consumed by uncontrolled pain, they often fear the
process of dying more than death itself. Quality of life (QOL)
issues are particularly relevant for terminally ill cancer patients
receiving palliative care. Side effects from chemotherapy or
radiation therapy can cause an array of traumatic side effects,
such as fatigue, sleep disturbance, anxiety, depression, nausea and
vomiting. Not finding adequate relief from these side effects with
traditional medicine, cancer patients are seeking the aid of
Complementary and Alternative Medicine (CAM). CAM is defined as a
group of diverse medical and health care systems, practices, and
products that are not generally considered part of conventional
medicine. Despite the emergent literature supporting the efficacy
of specific CAM modalities for managing side effects and symptoms
associated with cancer treatments, the exact nature of CAM usage in
chronically ill cancer patients (e.g., the characteristics of
patients who use CAM, and who don't, what type of CAM is used, and
whether they inform their physician) is not well documented.
Although the study of CAM use among the general population is
relatively wide-spread, less attention has been given to the study
of CAM use among patients receiving palliative care. This is a
grant proposal that will assess CAM therapies being utilized by
end-stage cancer patients receiving palliative care and
communication about CAM usage between the patients and physicians.
Table of Contents
Table of Contents Chapter I: Introduction 1 Problem Statement 2
Purpose Statement 2 Significance Statement… 2
Definition of Terms 3 Chapter II: Review of the Literature 5
Introduction 5 Review of the Literature 6 Summary of Current
Problem and Study Relevance 13 Chapter III: Methodology 14 Review
of Funding Agencies 14 Description of Grant Announcement 15 Review
Criteria 18 Investigators 19 Institutional Environment 22
Methodology of the Grant Review Process 25 Description of Grant
Reviewers 26 Protection of Human Subjects 27 Chapter IV:
Incorporation of Reviewer Comments 32 Reviewer 1 comments 32
Reviewer 2 comments 35 Reviewer 3 comments 40 Reviewer 4 comments
41 Reviewer 5 comments 42 Chapter V: Final Version of Grant
Proposal 54 Specific Aims 56 Research Strategy 58 Data Analysis 69
Investigators 71 Institutional Environment 74 Literature Cited 77
Appendix A: Informed Consent 84 Appendix B: Informed Consent
Documentation 89 Appendix C: HIPAA Identifiers 90 Appendix D: CAM
Questionnaire 92 Appendix E: RFA-AT-01-002 94 Appendix F:
Instructions for Review Process 104 Appendix G: External Review
Evaluation Scoring Sheet 105 Appendix H: Conflict of Interest 109
Appendix I: Assessment of Quality of Life at the End of Life
Questionnaire (AQEL) 112 Appendix J: ECOG Scale of Performance
Status 113
About this Master's Thesis
Rights statement
- Permission granted by the author to include this thesis or dissertation in this repository. All rights reserved by the author. Please contact the author for information regarding the reproduction and use of this thesis or dissertation.
| School |
|
|---|
| Department |
|
|---|
| Degree |
|
|---|
| Submission |
|
|---|
| Language |
|
|---|
| Research Field |
|
|---|
| 关键词 |
|
|---|
| Committee Chair / Thesis Advisor |
|
|---|
| Committee Members |
|
|---|
| Partnering Agencies |
|
|---|